Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV

NCT ID NCT06684379

Recruiting now Disease control Sponsor: PEACHES BIOTECH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called PRS CK STORM, made from a mix of immune and fat cells, to see if it can safely calm the 'cytokine storm'—a dangerous overreaction of the immune system—in people with severe lung infections from COVID-19, flu, or RSV. The study will enroll 50 adults who need oxygen therapy and compare two doses of the drug against a placebo. The main goals are to check safety and to see if the drug reduces inflammation and improves breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRS CK STORM (a liquid made from immune and fat cells)
What this could lead to: If it works, this could provide a new way to calm the dangerous overreaction of the immune system (cytokine storm) in severe respiratory infections.
What could go wrong: This is a very early (Phase 1/2) pilot study with only 50 people. It is primarily testing safety, so effectiveness is not yet proven. The treatment is experimental and may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY INFECTION CAUSED BY INFLUENZA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult acute respiratory distress syndrome COVID-19 cytokine release syndrome influenza lung disorder pneumonia respiratory distress syndrome in premature infants respiratory syncytial virus infectious disease Systemic Inflammatory Response Syndrome viral pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA, HUMAN RESPIRATORY DISTRESS SYNDROME RESPIRATORY SYNCYTIAL VIRUS INFECTIONS SARS-COV-2 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

Contacts and locations

Locations

Hospital Universitario Príncipe de Asturias
RECRUITING

Alcalá de Henares, Madrid, 28805, Spain
Hospital Universitario Reina Sofía
RECRUITING

Córdoba, 14004, Spain
Hospital Universitario de Fuenlabrada
RECRUITING

Fuenlabrada, Madrid, 28942, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.